EVALUATION ON USE cisplatin-based chemotherapy antiemetic CANCER PATIENTS IN HOSPITAL CANCER DHARMAIS JAKARTA
ABSTRACT: The overcome the side effects of nausea and vomiting associated with administration of cancer drugs are often given anti nausea antiemetic. Givin antiemetic to treat nausea and vomiting can maintain the quality of life patients who undergo chemotherapy. This study aimed to evaluate the use of general antiemetic in cancer patients during chemotherapy cisplatin or cisplatin combination Dharmais Cancer Hospital Jakarta period January-October 2012. This study is an observational study with retrospective data collection and data analysis is descriptive and anlytical. This research was conducted in the Installation notes Dharmais Cancer Hospital Medical Record Jakarta based on medical records during the period January to October 2012. The result of the study there were 30 cancer patients who received an antiemetic drug alone or in combination as many as 6 patients (20%) using ondansetron, 14 patients (46,67%) using ondansetron + dexamethasone, 6 patients (20%) using ondansetron + metoclopramide, 1 patients (3,33%) using ondansetron + methylprednisolone + dexamethasone, 1 patients (3,33%) using trofisetron + Methylprednisolon, 1 patients (3,33%) using trofisetron + metoclopramide and 1 patients (3,33%) trofisetron + metoclopramide + dexamethasone. From the research cisplatin chemotherapy regiments cisplatin + paclitaxel (severe and moderate emetogenic level) with a combination antiemetic ondansetron + metoclopramide experiencing emesis by 4 patients (13,33%). While the regimen of cisplatin + docetaxel (severe and moderate emetogenic level) by using a combination antiemetic ondansetron + dexamethasone did not experience emesis by 2 patients (6,67%). Cisplatin regimen + docetaxel + 5FU (level High + moderate + moderate) by using a combination antiemetic ondansetron + dexamethasone experienced emesis events were 11 patients (36,67). Keyword : chemotherapy, side effects of nausea vomiting, cancer patients, antiemetics
ABSTRACT: The overcome the side effects of nausea and vomiting associated with administration of cancer drugs are often given anti nausea antiemetic. Givin antiemetic to treat nausea and vomiting can maintain the quality of life patients who undergo chemotherapy. This study aimed to evaluate the use of general antiemetic in cancer patients during chemotherapy cisplatin or cisplatin combination Dharmais Cancer Hospital Jakarta period January-October 2012. This study is an observational study with retrospective data collection and data analysis is descriptive and anlytical. This research was conducted in the Installation notes Dharmais Cancer Hospital Medical Record Jakarta based on medical records during the period January to October 2012. The result of the study there were 30 cancer patients who received an antiemetic drug alone or in combination as many as 6 patients (20%) using ondansetron, 14 patients (46,67%) using ondansetron + dexamethasone, 6 patients (20%) using ondansetron + metoclopramide, 1 patients (3,33%) using ondansetron + methylprednisolone + dexamethasone, 1 patients (3,33%) using trofisetron + Methylprednisolon, 1 patients (3,33%) using trofisetron + metoclopramide and 1 patients (3,33%) trofisetron + metoclopramide + dexamethasone. From the research cisplatin chemotherapy regiments cisplatin + paclitaxel (severe and moderate emetogenic level) with a combination antiemetic ondansetron + metoclopramide experiencing emesis by 4 patients (13,33%). While the regimen of cisplatin + docetaxel (severe and moderate emetogenic level) by using a combination antiemetic ondansetron + dexamethasone did not experience emesis by 2 patients (6,67%). Cisplatin regimen + docetaxel + 5FU (level High + moderate + moderate) by using a combination antiemetic ondansetron + dexamethasone experienced emesis events were 11 patients (36,67). Keyword : chemotherapy, side effects of nausea vomiting, cancer patients, antiemetics
